Customer story


Customer story in numbers


Million € funding

Funding instrument

Horizon 2020 SME instrument Phase 2

Affordable, accessible and automatic screening solution for diabetic retinopathy: Smartscope-X.

This solution consists of 3 main components: a low-cost handheld camera, an automated screening algorithm and cloud service for eyeground images. The SME Phase 2 project leads the way by making Smartscope-X the leading solution for diabetic retinopathy screening. It supports Optomed’s vision to provide affordable eye screenings to everyone.

Diabetic retinopathy is a diabetic condition and it is the most frequent cause of preventable blindness in working-aged adults and affects people with all types of diabetes.

It is estimated that by 2040, 1 in 10 people will have diabetes and through an early and effective screening process, visual impairment and blindness caused by diabetic retinopathy can be prevented.

Current screening is costly, takes time and needs to be done by an ophthalmologist

How we reached the goals

Spinverse helped by providing support in project preparation, including help in defining the scope, matching the call and assisting in the proposal writing. After a positive decision from the EU Commission, Spinverse supported Optomed in the project negotiation phase.

Key takeaways

Optomed needed funding to validate and commercialise a fully automated diabetic retinopathy screening solution. Because Smartscope-X is a low-cost & portable solution, it is also suitable in areas with limited access to screening, for example in developing countries.

Contact Us

Do you want to find out how Spinverse could help you? Contact us today!

Riikka Paasikivi

Senior Consultant, M.Sc. (Chem.Eng.)

+358 50 521 5944

You might be interested in